|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
ATE318923T1
(de)
|
2000-06-01 |
2006-03-15 |
Univ North Carolina |
Doppelsträngige parvovirus-vektoren
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
AU2002228841C1
(en)
|
2000-12-07 |
2006-11-23 |
Sangamo Biosciences, Inc |
Regulation of angiogenesis with zinc finger proteins
|
|
AU2002225187A1
(en)
|
2001-01-22 |
2002-07-30 |
Sangamo Biosciences, Inc. |
Zinc finger polypeptides and their use
|
|
WO2002057293A2
(en)
|
2001-01-22 |
2002-07-25 |
Sangamo Biosciences, Inc. |
Modified zinc finger binding proteins
|
|
US20030108524A1
(en)
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
|
EP1308517A1
(en)
|
2001-10-31 |
2003-05-07 |
Aventis Pharmacueticals Products Inc. |
Vectors for expressing multiple transgenes
|
|
WO2003087341A2
(en)
|
2002-01-23 |
2003-10-23 |
The University Of Utah Research Foundation |
Targeted chromosomal mutagenesis using zinc finger nucleases
|
|
WO2003080809A2
(en)
|
2002-03-21 |
2003-10-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
EP2806025B1
(en)
|
2002-09-05 |
2019-04-03 |
California Institute of Technology |
Use of zinc finger nucleases to stimulate gene targeting
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
AU2005287278B2
(en)
|
2004-09-16 |
2011-08-04 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
EP2027262B1
(en)
|
2006-05-25 |
2010-03-31 |
Sangamo Biosciences Inc. |
Variant foki cleavage half-domains
|
|
ES2465996T3
(es)
|
2006-05-25 |
2014-06-09 |
Sangamo Biosciences, Inc. |
Métodos y composiciones para la inactivación genética
|
|
ES2586210T3
(es)
|
2006-12-14 |
2016-10-13 |
Sangamo Biosciences, Inc. |
Proteínas de dedo de zinc no canónicas optimizadas
|
|
DE602008003684D1
(de)
|
2007-04-26 |
2011-01-05 |
Sangamo Biosciences Inc |
Gezielte integration in die ppp1r12c-position
|
|
JP2011517838A
(ja)
|
2008-04-11 |
2011-06-16 |
ユーティーシー パワー コーポレイション |
マニホルド・サンプを備えたバイポーラプレートおよび燃料電池
|
|
EP2352369B1
(en)
|
2008-12-04 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2408921B1
(en)
|
2009-03-20 |
2017-04-19 |
Sangamo BioSciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
EP2456877A4
(en)
|
2009-07-24 |
2012-05-30 |
Sigma Aldrich Co Llc |
METHOD OF GENOMIC PROCESSING
|
|
WO2011017293A2
(en)
|
2009-08-03 |
2011-02-10 |
The General Hospital Corporation |
Engineering of zinc finger arrays by context-dependent assembly
|
|
US8586526B2
(en)
|
2010-05-17 |
2013-11-19 |
Sangamo Biosciences, Inc. |
DNA-binding proteins and uses thereof
|
|
US8518392B2
(en)
|
2009-08-14 |
2013-08-27 |
Regeneron Pharmaceuticals, Inc. |
Promoter-regulated differentiation-dependent self-deleting cassette
|
|
CA2779858C
(en)
|
2009-10-29 |
2019-10-29 |
Regeneron Pharmaceuticals, Inc. |
Multifunctional alleles
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
CN105755044A
(zh)
*
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
CA2848417C
(en)
|
2011-09-21 |
2023-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
CA3099582A1
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
WO2013141680A1
(en)
|
2012-03-20 |
2013-09-26 |
Vilnius University |
RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
EP2839013B1
(en)
|
2012-04-18 |
2020-08-26 |
The Board of Trustees of the Leland Stanford Junior University |
Non-disruptive gene targeting
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
EP3196301B1
(en)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of monogenic diseases
|
|
WO2014033644A2
(en)
|
2012-08-28 |
2014-03-06 |
Novartis Ag |
Methods of nuclease-based genetic engineering
|
|
AU2013335451C1
(en)
|
2012-10-23 |
2024-07-04 |
Toolgen Incorporated |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
|
US9255250B2
(en)
|
2012-12-05 |
2016-02-09 |
Sangamo Bioscience, Inc. |
Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
DK2931891T3
(da)
|
2012-12-17 |
2019-08-19 |
Harvard College |
Rna-styret modificering af menneskelige genomer
|
|
WO2014127196A1
(en)
*
|
2013-02-15 |
2014-08-21 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Aav8 retinoschisin expression vector for treating x-linked retinoschisis
|
|
US10350306B2
(en)
*
|
2013-02-15 |
2019-07-16 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Methods and compositions for treating genetically linked diseases of the eye
|
|
MX384291B
(es)
|
2013-02-20 |
2025-03-14 |
Regeneron Pharma |
Modificación genética de ratas.
|
|
EP2922393B2
(en)
|
2013-02-27 |
2022-12-28 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Gene editing in the oocyte by cas9 nucleases
|
|
CN112301024A
(zh)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
|
|
EP4286517A3
(en)
|
2013-04-04 |
2024-03-13 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
CN105683376A
(zh)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
用于治疗遗传病状的方法和组合物
|
|
CN105683379A
(zh)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
DE102013111099B4
(de)
|
2013-10-08 |
2023-11-30 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
|
|
CN105940013B
(zh)
|
2013-12-09 |
2020-03-27 |
桑格摩生物科学股份有限公司 |
用于治疗血友病的方法和组合物
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
WO2015127439A1
(en)
|
2014-02-24 |
2015-08-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration
|
|
BR112016019940A2
(pt)
|
2014-03-21 |
2017-10-24 |
Univ Leland Stanford Junior |
edição de genoma sem nucleases
|
|
EP3155116A4
(en)
|
2014-06-10 |
2017-12-27 |
Massachusetts Institute Of Technology |
Method for gene editing
|
|
ES2788426T3
(es)
|
2014-06-16 |
2020-10-21 |
Univ Johns Hopkins |
Composiciones y métodos para la expresión de ARNs de guía de CRISPR utilizando el promotor de H1
|
|
US20150376586A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
CN106794141B
(zh)
|
2014-07-16 |
2021-05-28 |
诺华股份有限公司 |
将核酸包封在脂质纳米粒主体中的方法
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
WO2016106121A1
(en)
|
2014-12-23 |
2016-06-30 |
Syngenta Participations Ag |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
KR102888521B1
(ko)
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
EP3289080B1
(en)
|
2015-04-30 |
2021-08-25 |
The Trustees of Columbia University in the City of New York |
Gene therapy for autosomal dominant diseases
|
|
WO2016179038A1
(en)
|
2015-05-01 |
2016-11-10 |
Spark Therapeutics, Inc. |
ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
US11279928B2
(en)
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
EP3159407A1
(en)
|
2015-10-23 |
2017-04-26 |
Silence Therapeutics (London) Ltd |
Guide rnas, methods and uses
|
|
BR112018008971A2
(pt)
|
2015-11-06 |
2018-11-27 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
|
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
|
US10639383B2
(en)
|
2015-11-23 |
2020-05-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CN109715801B
(zh)
|
2015-12-01 |
2022-11-01 |
克里斯普治疗股份公司 |
用于治疗α1抗胰蛋白酶缺乏的材料和方法
|
|
KR20180118111A
(ko)
|
2015-12-23 |
2018-10-30 |
크리스퍼 테라퓨틱스 아게 |
근위축성 측색 경화증 및/또는 전두측두엽 퇴행의 치료 물질 및 방법
|
|
US20190038771A1
(en)
|
2016-02-02 |
2019-02-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
EP3416689B1
(en)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
|
LT3436077T
(lt)
|
2016-03-30 |
2025-06-25 |
Intellia Therapeutics, Inc. |
Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
|
WO2018013720A1
(en)
|
2016-07-12 |
2018-01-18 |
Washington University |
Incorporation of internal polya-encoded poly-lysine sequence tags and their variations for the tunable control of protein synthesis in bacterial and eukaryotic cells
|
|
EP4321623A3
(en)
|
2016-07-15 |
2024-05-15 |
Salk Institute for Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
WO2020046861A1
(en)
|
2018-08-27 |
2020-03-05 |
Avellino Lab Usa, Inc. |
Crispr/cas9 systems, and methods of use thereof
|
|
CA3035534A1
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
CA3034931A1
(en)
|
2016-09-23 |
2018-03-29 |
Board Of Trustees Of Southern Illinois University |
Tuning crispr/cas9 activity with chemically modified nucleotide substitutions
|
|
SG10202106058WA
(en)
|
2016-12-08 |
2021-07-29 |
Intellia Therapeutics Inc |
Modified guide rnas
|
|
AU2017374042C1
(en)
|
2016-12-09 |
2024-07-11 |
Acuitas Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
AU2017378427A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
|
US11597947B2
(en)
|
2016-12-29 |
2023-03-07 |
Asc Therapeutics Inc. |
Gene editing method using virus
|
|
WO2018154459A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
|
CN118581154A
(zh)
|
2017-06-02 |
2024-09-03 |
国家健康与医学研究院 |
用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法
|
|
JP7123982B2
(ja)
|
2017-06-15 |
2022-08-23 |
ツールゲン インコーポレイテッド |
肝臓において目的のタンパク質を発現するためのプラットフォーム
|
|
US11981898B2
(en)
|
2017-06-16 |
2024-05-14 |
Applied Stemcell, Inc. |
Gene editing methods with increased knock-in efficiency
|
|
WO2019010384A1
(en)
|
2017-07-07 |
2019-01-10 |
The Broad Institute, Inc. |
METHODS FOR DESIGNING GUIDE SEQUENCES FOR GUIDED NUCLEASES
|
|
CN111094573A
(zh)
|
2017-07-12 |
2020-05-01 |
梅约医学教育与研究基金会 |
有效靶向敲入或基因置换的材料和方法
|
|
US20200231974A1
(en)
|
2017-07-18 |
2020-07-23 |
Genovie Ab |
A two-component vector library system for rapid assembly and diversification of full-length t-cell receptor open reading frames
|
|
CN110891420B
(zh)
|
2017-07-31 |
2022-06-03 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
|
CA3072960A1
(en)
|
2017-08-15 |
2019-02-21 |
Intellia Therapeutics, Inc. |
Stabilized nucleic acids encoding messenger ribonucleic acid (mrna)
|
|
US20230140670A1
(en)
|
2017-09-29 |
2023-05-04 |
Intellia Therapeutics, Inc. |
Formulations
|
|
WO2019067910A1
(en)
|
2017-09-29 |
2019-04-04 |
Intellia Therapeutics, Inc. |
POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION
|
|
MA50833A
(fr)
|
2017-10-17 |
2020-08-26 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique pour l'hémophilie a
|
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
|
CA3082450A1
(en)
|
2017-11-21 |
2019-05-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
CA3084185A1
(en)
|
2017-12-06 |
2019-06-13 |
Generation Bio Co. |
Gene editing using a modified closed-ended dna (cedna)
|
|
WO2019118875A1
(en)
|
2017-12-15 |
2019-06-20 |
Ou Li |
Crispr-mediated genome editing with vectors
|
|
EP3728598A1
(en)
|
2017-12-21 |
2020-10-28 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Nucleic acid sequence replacement by nhej
|
|
WO2019134561A1
(en)
|
2018-01-05 |
2019-07-11 |
The Chinese University Of Hong Kong |
High efficiency in vivo knock-in using crispr
|
|
CA3088180A1
(en)
|
2018-01-12 |
2019-07-18 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting transferrin
|
|
MA51869A
(fr)
|
2018-02-16 |
2020-12-23 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha
|
|
CN112153990A
(zh)
*
|
2018-03-23 |
2020-12-29 |
纽约市哥伦比亚大学理事会 |
用于常染色体显性疾病的基因编辑
|
|
EP3787694A4
(en)
|
2018-04-29 |
2022-05-18 |
University of Massachusetts |
RAAV-MEDIATED NUCLEASE-ASSOCIATED VECTOR INTEGRATION (RAAV-NAVI)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
AU2019282824C1
(en)
|
2018-06-08 |
2026-04-23 |
Intellia Therapeutics, Inc. |
Modified guide RNAS for gene editing
|
|
WO2019239361A1
(en)
|
2018-06-14 |
2019-12-19 |
Novartis Ag |
Method for sequence insertion using crispr
|
|
CA3103528A1
(en)
|
2018-06-19 |
2019-12-26 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
|
|
US12264181B2
(en)
|
2018-06-27 |
2025-04-01 |
Altius Institute For Biomedical Sciences |
Nucleic acid binding domains and methods of use thereof
|
|
US12209259B2
(en)
|
2018-06-27 |
2025-01-28 |
Altius Institute For Biomedical Sciences |
Nucleases for genome editing
|
|
WO2020006132A1
(en)
|
2018-06-27 |
2020-01-02 |
Altius Institute For Biomedical Sciences |
Gapped and tunable repeat units for use in genome editing and gene regulation compositions
|
|
AU2019293286A1
(en)
|
2018-06-28 |
2021-01-07 |
Crispr Therapeutics Ag |
Compositions and methods for genomic editing by insertion of donor polynucleotides
|
|
WO2020014577A1
(en)
|
2018-07-13 |
2020-01-16 |
Allele Biotechnology And Pharmaceuticals, Inc. |
Methods of achieving high specificity of genome editing
|
|
MA53252A
(fr)
|
2018-08-10 |
2021-09-15 |
Logicbio Therapeutics Inc |
Thérapie génique non perturbatrice pour le traitement d'un mma
|
|
US20210180045A1
(en)
|
2018-08-31 |
2021-06-17 |
The Children's Hospital Of Philadelphia |
Scalable tagging of endogenous genes by homology-independent intron targeting
|
|
WO2020055941A1
(en)
|
2018-09-13 |
2020-03-19 |
Excision Biotherapeutics, Inc. |
Compositions and methods for excision with single grna
|
|
US20220009878A1
(en)
|
2018-10-02 |
2022-01-13 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
JP2022505139A
(ja)
|
2018-10-15 |
2022-01-14 |
フォンダッツィオーネ・テレソン |
ゲノム編集の方法及び構築物
|
|
SG11202103917VA
(en)
|
2018-10-16 |
2021-05-28 |
Blueallele Llc |
Methods for targeted insertion of dna in genes
|
|
JP7520826B2
(ja)
|
2018-10-17 |
2024-07-23 |
クリスパー・セラピューティクス・アクチェンゲゼルシャフト |
導入遺伝子を送達するための組成物および方法
|
|
AU2019359890B2
(en)
|
2018-10-17 |
2024-10-24 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US20200270617A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for transgene expression from an albumin locus
|
|
AU2019360270B2
(en)
|
2018-10-18 |
2025-08-07 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX.
|
|
CN113272428A
(zh)
|
2018-10-18 |
2021-08-17 |
英特利亚治疗股份有限公司 |
核酸构建体和使用方法
|
|
WO2020082047A1
(en)
|
2018-10-18 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiencey
|
|
CN113710799B
(zh)
|
2018-11-28 |
2024-11-12 |
克里斯珀医疗股份公司 |
用于在LNP中使用的编码CAS9的优化mRNA
|
|
BR112021010853A2
(pt)
|
2018-12-05 |
2021-08-31 |
Intellia Therapeutics, Inc. |
Lipídios de amina modificados
|
|
SG11202108357PA
(en)
|
2019-02-15 |
2021-08-30 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
|
WO2020210552A1
(en)
|
2019-04-11 |
2020-10-15 |
California Institute Of Technology |
Methods and compositions for in vivo gene editing based cell-type-specific cellular engineering
|
|
CN114127044A
(zh)
|
2019-04-25 |
2022-03-01 |
英特利亚治疗股份有限公司 |
可电离的胺类脂质和脂质纳米颗粒
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
AU2021246006A1
(en)
|
2020-03-30 |
2022-10-20 |
Blueallele, Llc |
Methods for integrating DNA into genes with gain-of-function or loss-of-function mutations
|
|
EP4146284A1
(en)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|